Equities

SeaStar Medical Holding Corp

ICU:NAQ

SeaStar Medical Holding Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)4.53
  • Today's Change-0.43 / -8.67%
  • Shares traded101.13k
  • 1 Year change-12.88%
  • Beta-1.0995
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SeaStar Medical Holding Corporation is a commercial-stage medical technology company. The Company is focused on developing extracorporeal therapies to reduce the consequences of hyperinflammation on vital organs. The Company's technologies rely on science to provide life-saving solutions to critically ill patients. The Company develops and commercializes cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company uses its Selective Cytopheretic Device (SCD) technology platform to clinically validate several acute organ injury indications, including kidneys and lungs. Its investigational SCD is an extracorporeal synthetic membrane device designed to integrate into existing continuous renal replacement therapy (CRRT) systems that are commonly installed in hospitals throughout the United States.

  • Revenue in USD (TTM)0.00
  • Net income in USD-33.23m
  • Incorporated2020
  • Employees12.00
  • Location
    SeaStar Medical Holding Corp3513 Brighton Blvd, Suite 410DENVER 80216United StatesUSA
  • Phone+1 (813) 362-6488
  • Fax+1 (302) 655-5049
  • Websitehttps://seastarmedical.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Autonomix Medical Inc-100.00bn-100.00bn15.01m5.00--2.37----------0.2749----------------------------0.1647-------674.99------
LiveCare Inc0.00-2.34m15.26m----6.47-----0.1411-0.14110.000.04630.00-------424.83---550.62-------------8.180.1888-------344.86------
Cutera Inc169.19m-148.97m15.50m430.00------0.0916-7.46-7.468.46-10.730.45722.083.86393,460.50-40.25-22.00-51.64-30.728.1847.63-88.05-27.242.17-31.342.05---15.865.47-97.76--85.87--
Innovative Eyewear Inc1.53m-7.86m15.53m11.00--2.06--10.15-11.01-11.012.054.810.17791.9715.91139,070.90-91.45---96.06---2.46---514.10--12.85--0.00--74.67---17.28------
BioRegenx Inc634.81k-727.95k17.12m10.00--1.01--26.97-0.001-0.0010.00160.01780.0617----63,481.00-7.07---8.46--74.90---114.67--0.1547-8.800.0977---47.25---629.37------
PAVmed Inc3.83m-67.35m17.17m107.00------4.48-8.17-8.170.4595-7.740.0823--29.4535,785.05-155.93-154.56---1,152.82-77.59---1,895.64-8,764.890.5529-8.161.74--550.40--25.76--55.51--
Beyond Air Inc1.78m-58.35m17.78m107.00--1.09--9.97-1.65-1.650.04850.35140.02981.706.8716,663.55-104.22-78.25-137.64-99.91-78.30---3,493.78-6,152.992.42-38.110.4666-----31.57-7.93--152.05--
Spectral AI Inc22.53m-20.24m19.01m78.00------0.8439-1.48-1.481.55-0.24221.68--11.54288,859.00-150.54---954.46--45.12---89.85--0.7066--2.14---28.82---616.14------
Neuraxis Inc2.27m-15.26m20.05m19.00------8.84-3.09-3.090.4039-0.76861.096.6311.80119,318.90-731.17------87.29---672.94--0.2724-19.01-----8.37---163.78------
SeaStar Medical Holding Corp0.00-33.23m20.79m12.00---------21.41-21.410.00-2.140.00----0.00-1,145.80-----------------9.51---------115.19------
Inspira Technologies Oxy BHN Ltd0.00-11.29m23.23m37.00--3.44-----0.9549-0.95490.000.36660.00----0.00-88.60-114.98-108.36-159.56------------0.00------24.64------
IR-Med Inc0.00-3.47m24.05m6.00--66.22-----0.0499-0.04990.000.00510.00----0.00-197.95---273.36--------------0.3019-------3.70------
Orgenesis Inc662.00k-29.02m25.81m146.00------38.99-0.8684-0.86840.02-0.33030.027278.295.384,534.25-122.18---1,312.10---101.06---4,489.28--0.0741-5.85-----98.53-50.94-271.82---17.71--
Femasys Inc950.09k-16.69m26.01m32.00--2.31--27.38-0.8468-0.84680.04720.50600.05490.34387.6529,690.31-96.51---108.58--65.67---1,756.83--5.93-77.250.2972---11.13---25.04------
Meihua International Medical Tech Co Ltd97.10m11.63m26.22m617.002.120.16852.170.2700.48560.48564.066.110.578846.661.31157,372.606.9112.268.1315.0534.1938.1411.9415.475.21--0.04750.00-6.055.1086.22-5.56-9.16--
Data as of Sep 20 2024. Currency figures normalised to SeaStar Medical Holding Corp's reporting currency: US Dollar USD

Institutional shareholders

4.06%Per cent of shares held by top holders
HolderShares% Held
BofA Securities, Inc.as of 30 Jun 202433.37k0.80%
Geode Capital Management LLCas of 30 Jun 202431.02k0.74%
UBS Securities LLCas of 30 Jun 202429.06k0.69%
The Vanguard Group, Inc.as of 30 Jun 202426.02k0.62%
Thrivent Trust Co.as of 30 Jun 202422.18k0.53%
BlackRock Fund Advisorsas of 30 Jun 20249.13k0.22%
Morgan Stanley & Co. LLCas of 30 Jun 20247.70k0.18%
Barclays Bank Plc (Private Banking)as of 30 Jun 20245.83k0.14%
Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Jun 20244.20k0.10%
Vanguard Global Advisers LLCas of 30 Jun 20241.64k0.04%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.